Evidence map›Paper›PMID 37802470›Full record

ArticleThe Journal of infection2023

Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.

Shen Tian, Ti Liu, Xin-Jing Zhao, Xiao-Lin Liu, Xin-Lou Li, Kai-Ge Du, Li-Qun Fang, Zeng-Qiang Kou, Yue-Hong Wei, Guo-Lin Wang

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in The Journal of infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shen TianState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China; Institute of Public Health, Guangzhou Medical University, Guangzhou, PR China; Guangzhou Center for Disease Control and Prevention, Guangzhou, PR China.
Ti LiuShandong Center for Disease Control and Prevention, Jinan, PR China.
Xin-Jing ZhaoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China; Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, PR China.
Xiao-Lin LiuShandong Center for Disease Control and Prevention, Jinan, PR China.
Xin-Lou LiDepartment of Medical Research, Key Laboratory of Environmental Sense Organ Stress and Health of the Ministry of Ecology and Environment, PLA Strategic Support Force Medical Center, Beijing, PR China.
Kai-Ge DuShandong Center for Disease Control and Prevention, Jinan, PR China.
Li-Qun FangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China; Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, Hefei, PR China. Electronic address: fang_lq@163.com.
Zeng-Qiang KouShandong Center for Disease Control and Prevention, Jinan, PR China. Electronic address: jack-cou@163.com.
Yue-Hong WeiInstitute of Public Health, Guangzhou Medical University, Guangzhou, PR China; Guangzhou Center for Disease Control and Prevention, Guangzhou, PR China. Electronic address: wei_yh0928@163.com.
Guo-Lin WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, PR China. Electronic address: guolin_wang2019@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralHumansReinfectionAntibodies, NeutralizingAntibodies, Viral

Identifiers

PMID37802470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.